Richard D Carvajal

15PUBLICATIONS
146CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyChemotherapySatisfiability and optimisation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 08, 2026
Cancer Chemoimmunotherapy: Time Will Tell.

|Mar 05, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.

Michael S Gordon, Richard D Carvajal, Alexander Spira

|Sep 27, 2025
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.

Alexander N Shoushtari, Shaheer Khan, Kimberly Komatsubara

|Sep 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Takami Sato, Marcus O Butler, Sophie Piperno-Neumann

|Jul 11, 2025
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik

|Jun 12, 2023
Diversifying Eligibility to Enhance Real-World Results.

Fatima Fayyaz, Richard D Carvajal, Craig E Devoe

Pageof 3

Frequent Collaborators

3 joint publications

Takami Sato

3 joint publications

Marcus O Butler

3 joint publications

Alexander N Shoushtari

3 joint publications

Joseph J Sacco